Tag: xarelto
New VOYAGER PAD analysis confirms consistent benefit of low-dose rivaroxaban plus...
Data from a new prespecified analysis of the phase III VOYAGER PAD clinical trial show that low-dose rivaroxaban plus aspirin resulted in a 33%...
FDA approves expanded PAD indication for Xarelto plus aspirin to include...
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the US Food and Drug Administration (FDA) has approved an expanded peripheral arterial...
Janssen submits application to US FDA for new indication to expand...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the US Food and...
Positive NICE recommendation for Xarelto to prevent atherothrombotic events in CAD...
The National Institute for Health and Care Excellence (NICE) has published the final appraisal determination (FAD) recommending the use of Xarelto (rivaroxaban) by the...
Rivaroxaban recommended by NICE for peripheral and coronary artery disease patients
The National Institute for Health and Care Excellence (NICE) in the UK has published a positive draft final appraisal determination recommending the use of...
PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in...
Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at...
Rivaroxaban receives peripheral arterial disease indication in Europe and USA
Rivaroxaban (brand name Xarelto, Bayer) has received approval from the US Food and Drug Administration (FDA) and the European Commission to reduce risks in...
Bayer announces new licensed indication for use of Xarelto in patients...
Xarelto, co-administered with aspirin, is indicated in the EU for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or...
FDA approves new 10mg dosing for rivaroxaban to reduce continued risk...
Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous...
